Coherus Oncology, Inc. (CHRS)
Biological Products, (No Diagnostic Substances)
Latest Price
$1.33
TTM P/E
--
Normalized P/E
--
Div Yield
--
Book Value
0.42
P/B Ratio
3.18
Valuation metrics
adjust assumptions →EPS: $1.43
Book value / share: $0.50
Formula: √(22.5 × EPS × BVPS)
Graham Number
$4.03
+203% upside
Base FCF: $87M (median of recent 5yr)
Growth: 25%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$54.69
+4012% upside
EPS: $1.43
Target P/E: 15×
Formula: EPS × P/E
P/E Fair Value
$21.45
+1513% upside
Institutional Ownership
46.1% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Timothy G. Youngquist 2020 Irrevocable Trust | 13.05M | $18.0M | 8.45% | +759.8K | 2026-06-30 |
| BlackRock, Inc. | 12.00M | $16.0M | 7.77% | +1.64M | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.95M | $8.0M | 3.85% | +496.7K | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 3.69M | $5.0M | 2.39% | +564.0K | 2026-06-30 |
| SAMSARA BIOCAPITAL, LLC | 3.43M | $4.0M | 2.22% | -- | 2026-06-30 |
| Kohlberg Kravis Roberts & Co. L.P. | 3.04M | $4.0M | 1.97% | -- | 2026-06-30 |
| STATE STREET CORP | 2.38M | $3.0M | 1.54% | +56.4K | 2026-06-30 |
| TWO SIGMA INVESTMENTS, LP | 2.26M | $3.0M | 1.46% | -- | 2026-06-30 |
| CM Management, LLC | 2.10M | $2.0M | 1.36% | -- | 2026-06-30 |
| C WorldWide Group Holding A/S | 1.93M | $2.0M | 1.25% | -- | 2026-06-30 |